MacroLensNP नेपालीने Sign in Create accountSign up
Free · Microfinance

MATRI Matribhumi Laghubitta Bittiya Sanstha Limited

Rs 709.80 +9.20 (+1.31%) as of 2026-11-06 15:00:00
Open
700.00
High
709.80
Low
700.00
Prev. close
700.60
Volume
262
Turnover
1.86 lakh
Avg volume (30 d)
610
52-week low Rs 691.00
high Rs 1,048.50 -32.3% from the 52-week high

Matribhumi Laghubitta Bittiya Sanstha Limited (MATRI) is listed on the Nepal Stock Exchange in the Microfinance sector. Its share price is Rs 709.80 as of 6 November 2026, 32.3% below its 52-week high of Rs 1,048.50 and 2.7% above its 52-week low of Rs 691.00. It trades at a P/E of 15.7 on earnings per share of Rs 45.13, cheaper than the Microfinance sector's median P/E of 32.6.

We have no dividend record for MATRI. Promoters hold 70% of the shares and the public 30%.

Key figures latest report 2082/2083 Q4

Market value
446.01 crore · 4.46 arba
Shares listed
6,283,573
Paid-up capital
62.84 crore
EPS (annualised)
Rs 45.13
P/E
15.7
Book value / share
Rs 145.42
P/B
4.88
ROE
31.0%
ROA
2.32%
Dividend yield
0.00%
Net profit (annualised)
28.36 crore
Reserves
68.28 crore
Total assets
1,220 crore · 12.20 arba
Bad loans (NPL)
26.61%
Capital adequacy
6.09%
Credit to deposit
114.29%

Quarter by quarter trailing 12 months at each quarter

QuarterEPSEPS growth (y/y)Net profitRevenueROE
2082/2083 Q4 45.13 +589.3% * 28.36 crore 151.79 crore · 1.52 arba 29.5%
2082/2083 Q3 9.04 +197.9% * 5.68 crore 132.67 crore · 1.33 arba 5.5%
2082/2083 Q2 9.36 +136.1% * 5.88 crore 130.47 crore · 1.30 arba 5.3%
2082/2083 Q1 4.85 +107.1% * 3.05 crore 127.50 crore · 1.27 arba 2.5%
2081/2082 Q4 -9.22 – −5.79 crore 131.62 crore · 1.32 arba loss
2081/2082 Q3 -9.24 – −5.80 crore 130.76 crore · 1.31 arba loss
2081/2082 Q2 -25.92 – −16.29 crore 130.74 crore · 1.31 arba loss
2081/2082 Q1 -68.85 – −43.26 crore 138.44 crore · 1.38 arba loss

* A loss in this year or the year before: the change is measured against the size of last year's EPS - from -13.14 to -6.13 is +53.3%, the loss per share more than halved. Hover a figure for both years.

Dividends

No dividends recorded.

Who owns it

Promoters 70% Public 30%
Public float
1,885,072 shares
Mutual funds hold
0.0% of the float
Promoter lock-in
–

MacroLens analysis of MATRI

More on MATRI on the full desk The rating and verdict, fair value, dump risk and warning signs, the 12-month target, the buy / sell meter with every past signal, cornering and broker activity - the analysis behind every number above. Create an account - 7-day trial

Other Microfinance companies

CompanyPriceTodayP/EP/BMarket value
SKBBL Sana Kisan Bikas Laghubitta Bi... 762.00 +0.26% 51.13.38 3,755 crore · 37.55 arba
CBBL Chhimek Laghubitta Bittiya San... 987.00 -0.28% 27.53.93 3,570 crore · 35.70 arba
JBLB Jeevan Bikas Laghubitta Bittiy... 1,289.00 +0.62% 20.94.60 2,257 crore · 22.57 arba
NMFBS National Laghubitta Bittiya Sa... 1,192.40 +0.54% 20.44.27 1,814 crore · 18.14 arba
DDBL Deprosc Laghubitta Bittiya San... 862.50 -0.52% 17.93.80 1,773 crore · 17.73 arba
NUBL Nirdhan Utthan Laghubitta Bitt... 607.00 -1.30% 47.42.74 1,665 crore · 16.65 arba
SWBBL Swabalamban Laghubitta Bittiya... 724.00 0.00% 20.42.99 1,267 crore · 12.67 arba
FOWAD Forward Microfinance Laghubitt... 900.10 +0.57% 17.33.23 1,076 crore · 10.76 arba

Every Microfinance company 49

Browse all NEPSE stocks by sector →

MATRI: common questions

What is the share price of MATRI today?

MATRI (Matribhumi Laghubitta Bittiya Sanstha Limited) closed at Rs 709.80 as of 6 November 2026 on NEPSE.

Does MATRI pay dividends?

We have no dividend record for MATRI.

What is the P/E ratio of MATRI?

It trades at a P/E of 15.7 on earnings per share of Rs 45.13, cheaper than the Microfinance sector's median P/E of 32.6.

Is MATRI a good buy?

This page is not buy or sell advice. MacroLens NP rates every NEPSE company on its fundamentals - MATRI's rating, fair value, dump risk and broker activity are on the desk, free for 7 days.

Prices from NEPSE; figures from the company's quarterly reports; dividends, ownership and news from public filings. Research, not a recommendation to buy or sell - see the risk disclosure.